Illumina Appoints Eli Lilly's Chief Scientific Officer, Daniel Skovronsky, to Board of Directors
ILMN sits 80% above its 52-week low of $88.
Summary
Illumina appointed Daniel M. Skovronsky, M.D., Ph.D., Chief Scientific and Product Officer of Eli Lilly, to its Board of Directors, expanding the board to ten members.
Key Events · Executive and Board Changes · ILMN
-
New Independent Director Appointed
Illumina's Board of Directors increased its size from nine to ten members and appointed Daniel M. Skovronsky, M.D., Ph.D., effective June 16, 2026. Dr. Skovronsky qualifies as an independent director.
-
Strategic Expertise Added
Dr. Skovronsky currently serves as Chief Scientific and Product Officer of Eli Lilly and Company and President of Lilly Research Laboratories, bringing extensive experience in drug discovery, clinical development, and translational medicine to Illumina's board.
Analysis · ILMN · Industrial Applications And Services
Illumina has strengthened its Board of Directors by adding a highly experienced independent director with deep expertise in drug discovery and clinical development. Dr. Skovronsky's background as Chief Scientific and Product Officer at Eli Lilly and his leadership in advancing large research portfolios are directly relevant to Illumina's strategic focus on genomics, multiomics, and precision medicine, providing valuable guidance for the company's innovation efforts.
At the time of this filing, ILMN was trading at $158.38 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $24.4B. The 52-week trading range was $88.00 to $177.22. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.